BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

  October 1, 2024

   · 

  4 min read
• Press Releases

  Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

  October 1, 2024

   · 

  3 min read
• Press Releases

  New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

  October 1, 2024

   · 

  5 min read
• Press Releases

  Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis

  October 1, 2024

   · 

  2 min read
• Press Releases

  ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy

  October 1, 2024

   · 

  19 min read
• Press Releases

  Kraig Biocraft Laboratories Leverages New Production Center for Largest Ever Batch of Spider Silk Parental Lines

  October 1, 2024

   · 

  3 min read
• Press Releases

  Novellia and University of Alabama at Birmingham Study Examines Biomarker Testing Practices for Non-Small Cell Lung Cancer

  October 1, 2024

   · 

  3 min read
• Press Releases

  Prime Medicine Unveils Strategically Focused Pipeline

  October 1, 2024

   · 

  12 min read
• Press Releases

  NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

  October 1, 2024

   · 

  11 min read